Ifowem 2000mg Injection

Ifowem 2000mg Injection is an anti-cancer medication. It is used in the treatment of several types of cancer, including soft tissue sarcomas, germ cell cancer, pancreatic cancer, and cervical cancer. Its active ingredient is  Ifosfamide, which belongs to the group of alkylating anti-cancer agents. This chemotherapy medication works by disrupting the DNA of cancer cells, which prevents them from dividing and leads to cell death. Medicine can be used with other combinations of medications to increase the effectiveness of the treatment. A doctor's prescription is required to ensure safe and effective treatment.

• Soft tissue sarcomas
• Germ cell cancer
• Pancreatic cancer
• Cerv  ical cancer.

A doctor's prescription is recommended while using Ifowem 2000mg Injection, as it can cause several side effects that may be harmful to the body and affect the treatment. Consult the doctor if any of the symptoms persist:

• Hair loss
• Fever
• Phlebitis
• Liver toxicity
• Infections
• Immune system suppression
• Low levels of RBC, WBC, and platelets in the blood
• Bone marrow suppression
• Nerve toxicity
• Urinary problems
• Lung problems
• Kidney problem

Ifowem 2000mg Injection should be injected under the vein by a nurse or a doctor in a hospital or in a clinic. The medication can be used with or without food at the fixed time every day to enhance the effectiveness of the treatment. Never self-administer the medication dosage and duration to avoid complications.

Ifowem 2000mg Injection is an anti-cancer medication. The Injection works by damaging the DNA of cancer cells, which prevents them from growing and dividing. This leads to cancer cell death and helps slow or stop the tumor progression. The spread of cancer to other body parts of the body is reduced because the cancer cells are unable to multiply and survive.

• Furlanut, M., & Franceschi, L. (2003). Pharmacology of ifosfamide. Oncology, 65(Suppl. 2), 2-6. https://pubmed.ncbi.nlm.nih.gov/14586139/
• Klastersky, J. (2003). Side effects of ifosfamide. Oncology, 65(Suppl. 2), 7-10. https://pubmed.ncbi.nlm.nih.gov/14586140/
• Fleming, R. A. (1997). An overview of cyclophosphamide and ifosfamide pharmacology. Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 17(5P2), 146S-154S. https://pubmed.ncbi.nlm.nih.gov/9322882/
• Zhang, J., Tian, Q., & Zhou, S. F. (2006). Clinical pharmacology of cyclophosphamide and ifosfamide. Current Drug Therapy, 1(1), 55-84. https://www.benthamscience.com/article/133
• Nissim, I., Horyn, O., Daikhin, Y., Nissim, I., Luhovyy, B., Phillips, P. C., & Yudkoff, M. (2006). Ifosfamide-induced nephrotoxicity: mechanism and prevention. Cancer research, 66(15), 7824-7831. https://pubmed.ncbi.nlm.nih.gov/16885387/